Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. Rugo HS, Kaklamani V, McArthur H, Wander SA, et al. Clin Cancer Res 2025 Nov 14. doi: 10.1158/1078-0432.CCR-25-3040.

Read + Share

Amedeo Smart

Independent Medical Education

Rugo HS, Kaklamani V, McArthur H, Wander SA, et al. Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer. Clin Cancer Res 2025 Nov 14. doi: 10.1158/1078-0432.CCR-25-3040.
PMID: 41235919